Patents by Inventor Jorg Baumgarten
Jorg Baumgarten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080108576Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumour tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and ?v?3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumour cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.Type: ApplicationFiled: December 4, 2007Publication date: May 8, 2008Applicant: Bayer AktiengesellschaftInventors: Hans-Georg Lerchen, Jorg Baumgarten, Andreas Schoop, Markus Albers
-
Patent number: 7304037Abstract: The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumor tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and ?v?3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.Type: GrantFiled: March 8, 2002Date of Patent: December 4, 2007Assignee: Bayer AkiengesellschaftInventors: Hans-Georg Lerchen, Jörg Baumgarten, Andreas Schoop, Markus Albers
-
Patent number: 7220824Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and ?v?3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.Type: GrantFiled: August 28, 2000Date of Patent: May 22, 2007Assignee: Bayer AktiengesellschaftInventors: Hans-Georg Lerchen, Jörg Baumgarten, Ulf Brüggemeier, Markus Albers, Andreas Schoop, Thomas-J. Schulze
-
Publication number: 20060189544Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and ?v?3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.Type: ApplicationFiled: April 7, 2006Publication date: August 24, 2006Applicant: Bayer AktiengesellschaftInventors: Hans-Georg Lerchen, Jorg Baumgarten, Ulf Bruggemeier, Markus Albers, Andreas Schoop, Thomas Schulze
-
Patent number: 6943182Abstract: The invention relates to cyclopentabenzofuran derivatives, process for their preparation, the use of cyclopentabenzofuran derivatives for the production of a medicament for the therapy of NF-?B-dependent diseases and medicaments which contain the cyclopentabenzofuran derivatives.Type: GrantFiled: May 30, 2002Date of Patent: September 13, 2005Assignee: Bayer AktiengesellschaftInventors: Walter Guarnieri, Thomas Jaetsch, Andreas Schoop, Jörg Baumgarten, Axel Kretschmer, Horst-Peter Antonicek
-
Patent number: 6723718Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.Type: GrantFiled: July 25, 2002Date of Patent: April 20, 2004Assignee: Bayer AktiengesellschaftInventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
-
Patent number: 6649647Abstract: This invention relates to compounds containing a trioxane moiety, especially certain artemisinin derivatives, which have cytotoxic and antitumour activity and their use in the treatment of cancer. Some of these compounds comprise a ligand which is capable of binding to a nucleic acid and a group containing a trioxane moiety which is capable of acting as source of free radicals which are capable of chemically interacting with a nucleic acid. Processes for the preparation of such compounds and pharmaceutical compositions containing such compounds are also provided.Type: GrantFiled: April 15, 2002Date of Patent: November 18, 2003Inventors: Richard Haynes, Ho-Wai Chan, Wai-Lun Lam, Hing-Wo Tsang, Wen-Luan Hsiao, Hans-Georg Lerchen, Jörg Baumgarten
-
Publication number: 20030158424Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.Type: ApplicationFiled: July 25, 2002Publication date: August 21, 2003Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Muller, Jorg Baumgarten, Karsten von dem Bruch, Gerhard Muller, Udo Stropp, Ervin Horvath, Jean-Marie-Viktor de Vry, Rudy Schreiber
-
Publication number: 20030144334Abstract: The invention relates to cyclopentabenzofuran derivatives and their use preparation, the use of cyclopentabenzofuran derivatives for the production of a medicament for the therapy of NF-&kgr;B-dependent diseases and medicaments which contain the cyclopentabenzofuran derivatives.Type: ApplicationFiled: May 30, 2002Publication date: July 31, 2003Inventors: Walter Guarnieri, Thomas Jaetsch, Andreas Schoop, Jorg Baumgarten, Axel Kretschmer, Horst-Peter Antonicek
-
Patent number: 6518274Abstract: The invention relates to the use of cycloventabenzofuran derivatives for the production of a medicament for the treatment of nuclear factor of &kgr;B-dependent diseases.Type: GrantFiled: April 18, 2001Date of Patent: February 11, 2003Assignee: Bayer AktiengesellschaftInventors: Matthias Gehling, Jörg Baumgarten, Axel Kretschmer, Horst-Peter Antonicek, Peter Proksch, Bambang Wahyu Nugroho, Frank Bohnenstengel
-
Patent number: 6512007Abstract: The invention relates to the use of the substance known under the name of galiella lactone as pharmaceutical, in particular for the treatment of inflammatory processes.Type: GrantFiled: June 29, 2001Date of Patent: January 28, 2003Assignee: Bayer AktiengesellschaftInventors: Jörg Baumgarten, Marcus Weidler, Gerhard Erkel, Heidrun Anke, Timm Anke
-
Patent number: 6506734Abstract: The present invention relates to glycoconjugates of 20(S)-camptothecin, in which a 3-O-methylated &bgr;-L-fucose unit is linked to the 20-hydroxyl group of a camptothecin derivative via a thiourea-modified peptide spacer. The invention furthermore relates to processes for the preparation of the compounds according to the invention and to their use as medicaments, in particular in connection with oncoses.Type: GrantFiled: October 27, 1999Date of Patent: January 14, 2003Assignee: Bayer AktiengesellschaftInventors: Hans-Georg Lerchen, Karsten von dem Bruch, Jörg Baumgarten, Michael Sperzel
-
Publication number: 20020193311Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to &agr;v&bgr;3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumour tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and &agr;v&bgr;3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumour cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.Type: ApplicationFiled: March 8, 2002Publication date: December 19, 2002Inventors: Hans-Georg Lerchen, Jorg Baumgarten, Andreas Schoop, Markus Albers
-
Publication number: 20020183256Abstract: The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to &agr;v&bgr;3 integrin antagonists via preferred linking units which can be selevtively cleaved by enzymes such as metallo matrixproteases (MMPs), i.e. by enzymes which can especially be found in tumor tissue. The preferred linking units guarantee the serum stability of the conjugate of cytostatic and &agr;v&bgr;3 integrin antagonist and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.Type: ApplicationFiled: December 21, 2001Publication date: December 5, 2002Inventors: Hans-Georg Lerchen, Jorg Baumgarten, Oswald Lockhoff, Markus Albers, Andreas Schoop
-
Publication number: 20020173468Abstract: The present invention relates to conjugates of cytostatics and N-thiocarbonyl-modified amino acids or peptides, processes for their preparation and their use as medicaments, in particular in connection with carcinomatous disorders.Type: ApplicationFiled: June 7, 1999Publication date: November 21, 2002Inventors: HANS-GEORG LERCHEN, KARSTEN VON DEM BRUCH, JORG BAUMGARTEN, MICHAEL SPERZEL
-
Patent number: 6462074Abstract: The present invention relates to novel substituted (&agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.Type: GrantFiled: July 14, 2000Date of Patent: October 8, 2002Assignee: Bayer AktiengesellschaftInventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
-
Patent number: 6433004Abstract: The present invention relates to novel substituted &bgr;,&ggr;-fused lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.Type: GrantFiled: July 14, 2000Date of Patent: August 13, 2002Assignee: Bayer AktiengesellschaftInventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
-
Patent number: 6420393Abstract: The invention relates to cyclopentabenzofuran derivatives, processes for their preparation, the use of cyclopentabenzofuran derivatives for the production of a medicament for the therapy of NF-&kgr;B-dependent diseases and medicaments which contain the cyclopentabenzofuran derivatives.Type: GrantFiled: March 26, 2001Date of Patent: July 16, 2002Assignee: Bayer AktiengesellschaftInventors: Walter Guarnieri, Thomas Jaetsch, Andreas Schoop, Jörg Baumgarten, Axel Kretschmer, Horst-Peter Antonicek
-
Patent number: 6376539Abstract: The present invention relates to novel substituted bicyclic lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, cranial cerebral trauma, states of pain or CNS-mediated spasms.Type: GrantFiled: July 14, 2000Date of Patent: April 23, 2002Assignee: Bayer AktiengesellschaftInventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
-
Patent number: 6271342Abstract: The invention relates to cytostatics which, by modification with sugar, are tumor-specific. Suitable spacers ensure serum stability and at the same time an intracellular action.Type: GrantFiled: September 25, 1997Date of Patent: August 7, 2001Assignee: Bayer AktiengesellschaftInventors: Hans-Georg Lerchen, Karsten von dem Bruch, Uwe Petersen, Jörg Baumgarten, Norbert Piel, Horst-Peter Antonicek, Walter Weichel, Michael Sperzel, Klaus Dieter Bremm